Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 8/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16925032 | 1.00 | USP2 (0.37) | USP2SMN1; SMN2GPR119EPHX2NAMPT | |
| SCHEMBL30197578 | 1.00 | USP2 (0.37) | USP2SMN1; SMN2GPR119EPHX2NAMPT | |
| SCHEMBL30197599 | 1.00 | USP2 (0.37) | USP2SMN1; SMN2GPR119EPHX2NAMPT | |
| SCHEMBL16925343 | 1.00 | USP2 (0.37) | USP2SMN1; SMN2GPR119EPHX2NAMPT | |
| SCHEMBL31184432 | 1.00 | USP2 (0.37) | USP2SMN1; SMN2GPR119EPHX2NAMPT | |
| SCHEMBL30727455 | 1.00 | USP2 (0.37) | USP2SMN1; SMN2GPR119EPHX2NAMPT | |
| SCHEMBL29760900 | 1.00 | USP2 (0.37) | USP2SMN1; SMN2GPR119EPHX2NAMPT | |
| SCHEMBL20571735 | 1.00 | USP2 (0.37) | USP2SMN1; SMN2GPR119EPHX2NAMPT | |
| SCHEMBL22084450 | 1.00 | USP2 (0.37) | USP2SMN1; SMN2GPR119EPHX2NAMPT | |
| SCHEMBL20337453 | 1.00 | USP2 (0.37) | USP2SMN1; SMN2GPR119EPHX2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4317144-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (CN) | 2024-02-07 | — | — | EP | disclosed |
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-11873307-B2 | Manufacture of compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2024-01-16 | — | — | US | disclosed |
| US-11873307-B2 | Manufacture of compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2024-01-16 | — | — | US | disclosed |
| WO-2023071314-A1 | SYNTHESIS, PREPARATION METHOD AND USE OF SHP2 AND CDK4/6 DUAL-TARGET INHIBITORY COMPOUND | 中国药科大学 | 2023-05-04 | — | — | WO | disclosed |
| US-20230010886-A1 | SHP2 INHIBITORS AND USES THEREOF | Suzhou Puhe BioPharma Co., Ltd. (CN) | 2023-01-12 | — | — | US | disclosed |
| US-20220396585-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2022-12-15 | — | — | US | disclosed |
| US-11498930-B2 | Pyrimidine-fused cyclic compound, preparation method therefor and application thereof | Blueray Therapeutics (Shanghai) Co., Ltd (CN) | 2022-11-15 | — | — | US | disclosed |
| US-20210371429-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2021-12-02 | — | — | US | disclosed |
| US-11179397-B2 | Imidazopyrimidine derivatives | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20190185475-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-06-20 | — | — | US | disclosed |
| US-10308660-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2019-06-04 | — | — | US | disclosed |
| EP-3310779-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2019-05-08 | — | — | EP | disclosed |
| US-20180201623-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-07-19 | — | — | US | disclosed |
| US-20180201623-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-07-19 | — | — | US | disclosed |
| US-9938295-B2 | — | — | 2018-04-10 | — | — | US | disclosed |
| US-9938295-B2 | — | — | 2018-04-10 | — | — | US | disclosed |
| US-20170015680-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2017-01-19 | — | — | US | disclosed |
| US-20170015680-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2017-01-19 | — | — | US | disclosed |
| WO-2016203404-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230010886-A1 | SHP2 INHIBITORS AND USES THEREOF | PTPN1, PTPN7, PTPN18 | USP2 1852/4885SMN1; SMN2 3242/4885GPR119 934/4885 |
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | BCKDK, CYP11B2, HSD17B7 | USP2 4745/4885SMN1; SMN2 2421/4885GPR119 1235/4885 |
| US-11498930-B2 | Pyrimidine-fused cyclic compound, preparation method therefor and application thereof | PTPN11, PPM1F, PTPRF | USP2 3618/4885SMN1; SMN2 3594/4885GPR119 340/4885 |
| US-20180201623-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN5, PTPN1, PTPN7 | USP2 1924/4885SMN1; SMN2 2598/4885GPR119 1069/4885 |
| US-10308660-B2 | Compounds and compositions for inhibiting the activity of SHP2 | PTPN3, PTPN1, PTPN2 | USP2 2277/4885SMN1; SMN2 1937/4885GPR119 716/4885 |
| US-20220396585-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN5, PTPN1, PTPN7 | USP2 1924/4885SMN1; SMN2 2598/4885GPR119 1069/4885 |
| US-20190185475-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN3, PTPN5 | USP2 3908/4885SMN1; SMN2 3724/4885GPR119 604/4885 |
| US-20210371429-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN5, PTPN1, PTPN7 | USP2 1924/4885SMN1; SMN2 2598/4885GPR119 1069/4885 |
| US-11179397-B2 | Imidazopyrimidine derivatives | DPYD, KRAS, ABL1 | USP2 4022/4885SMN1; SMN2 356/4885GPR119 1872/4885 |
| US-20170015680-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN5, PTPN1, PTPN7 | USP2 1924/4885SMN1; SMN2 2598/4885GPR119 1069/4885 |
| US-11873307-B2 | Manufacture of compounds and compositions for inhibiting the activity of SHP2 | PTPN5, PTPN7, PTPN1 | USP2 2274/4885SMN1; SMN2 3717/4885GPR119 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.